1. Pink Sheet
  2. >>Geography

ICH Drafts Modernized Principles For E6 Good Clinical Practice Guide

 
• By Vibha Sharma

As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.

Clinical trial medicine, for the covid-19 coronavirus, on clipboard
ICH’s E6 guideline is a widely accepted standard for conducting trials globally • Source: Alamy

The International Council for Harmonisation has published a document offering a sneak preview of the new overarching principles that are to form the basis of its revised guideline on good clinical practice requirements (ICH E6 (R2)).

The ICH E6(R2) serves as an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

COVID-19 mRNA Vaccine Labels Now Quantify Myocarditis Risk, But ACIP Wants Other Changes

 
• By Sue Sutter

New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By Cathy Kelly

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 
• By Eliza Slawther

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”